Commonwealth Equity Services LLC Cuts Stake in Regeneron Pharmaceuticals, Inc. $REGN

Commonwealth Equity Services LLC decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,134 shares of the biopharmaceutical company’s stock after selling 1,621 shares during the period. Commonwealth Equity Services LLC’s holdings in Regeneron Pharmaceuticals were worth $9,072,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Salomon & Ludwin LLC acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $31,000. Traub Capital Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $38,000. Berbice Capital Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 300.0% in the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 60 shares during the period. Finally, Westside Investment Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 62.0% in the second quarter. Westside Investment Management Inc. now owns 81 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 31 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This represents a 46.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Jason Pitofsky sold 431 shares of the stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the sale, the vice president owned 4,233 shares in the company, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 8,431 shares of company stock valued at $5,733,521. 7.02% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Hsbc Global Res upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Royal Bank Of Canada upped their price target on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a research note on Wednesday, October 29th. Morgan Stanley increased their price target on shares of Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the company an “equal weight” rating in a report on Friday, December 12th. UBS Group raised their price objective on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Finally, Zacks Research upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 8th. Four analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $791.05.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $768.00 on Tuesday. The firm has a market capitalization of $80.72 billion, a PE ratio of 18.39, a P/E/G ratio of 2.16 and a beta of 0.39. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $821.11. The firm’s 50-day simple moving average is $740.64 and its 200 day simple moving average is $631.30. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, beating the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. During the same period last year, the firm posted $12.46 EPS. The firm’s revenue for the quarter was up .9% on a year-over-year basis. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.